Cosmo Pharmaceuticals Sa Stock Price To Earning
| COPN Stock | CHF 62.80 0.90 1.45% |
COSMO Pharmaceuticals SA fundamentals help investors to digest information that contributes to COSMO Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of COSMO Stock. The fundamental analysis module provides a way to measure COSMO Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to COSMO Pharmaceuticals stock.
COSMO |
COSMO Pharmaceuticals SA Company Price To Earning Analysis
COSMO Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current COSMO Pharmaceuticals Price To Earning | 95.06 X |
Most of COSMO Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, COSMO Pharmaceuticals SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, COSMO Pharmaceuticals SA has a Price To Earning of 95 times. This is 267.88% higher than that of the Healthcare sector and 105.49% higher than that of the Drug Manufacturers - Major industry. The price to earning for all Switzerland stocks is notably lower than that of the firm.
COSMO Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses COSMO Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of COSMO Pharmaceuticals could also be used in its relative valuation, which is a method of valuing COSMO Pharmaceuticals by comparing valuation metrics of similar companies.COSMO Pharmaceuticals is currently under evaluation in price to earning category among its peers.
COSMO Fundamentals
| Return On Equity | 0.0841 | |||
| Return On Asset | 0.0181 | |||
| Profit Margin | 0.45 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 960.99 M | |||
| Shares Outstanding | 16.38 M | |||
| Shares Owned By Insiders | 47.28 % | |||
| Shares Owned By Institutions | 11.80 % | |||
| Price To Earning | 95.06 X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 12.95 X | |||
| Revenue | 65.07 M | |||
| Gross Profit | 32.1 M | |||
| EBITDA | 40.36 M | |||
| Net Income | 21.67 M | |||
| Cash And Equivalents | 217.97 M | |||
| Cash Per Share | 14.53 X | |||
| Total Debt | 169.03 M | |||
| Debt To Equity | 35.50 % | |||
| Current Ratio | 24.38 X | |||
| Book Value Per Share | 28.23 X | |||
| Cash Flow From Operations | 12.61 M | |||
| Earnings Per Share | 2.13 X | |||
| Target Price | 86.03 | |||
| Number Of Employees | 292 | |||
| Beta | 1.07 | |||
| Market Capitalization | 1.12 B | |||
| Total Asset | 805.56 M | |||
| Z Score | 3.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 805.56 M | |||
| Last Dividend Paid | 0.95 |
About COSMO Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze COSMO Pharmaceuticals SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of COSMO Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of COSMO Pharmaceuticals SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for COSMO Stock Analysis
When running COSMO Pharmaceuticals' price analysis, check to measure COSMO Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSMO Pharmaceuticals is operating at the current time. Most of COSMO Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of COSMO Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSMO Pharmaceuticals' price. Additionally, you may evaluate how the addition of COSMO Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.